Table 2.
FATTY ACID VALUES AT BASELINE AND AFTER A 3-MONTH PLACEBO TREATMENT PERIOD
| Fatty Acids | Baseline | 3 months | % change | Wilcoxon P value | ||
|---|---|---|---|---|---|---|
| AA (μg/ml) | 235.46±62.62 | 238.77±46.73 | 4.19±17.82 | N.S. | ||
| AA (% TFA) | 7.81±1.91 | 7.97±1.47 | 3.49±9.13 | N.S. | ||
| DPA n-6 (μg/ml) | 7.42±1.62 | 8.14±2.42 | 11.96±30.8 | N.S. | ||
| DPA n-6 (% TFA) | 0.25±0.06 | 0.27±0.06 | 10.08±22.24 | N.S. | ||
| Tot LC n-6 (μg/ml) | 301.65±67.67 | 305.37±52.08 | 3.82±19.56 | N.S. | ||
| Tot LC n-6 (% TFA) | 9.98±1.85 | 10.16±1.49 | 2.70±7.95 | N.S. | ||
| EPA (μg/ml) | 14.55±4.77 | 13.62±4.89 | −1.57±31.68 | N.S. | ||
| EPA (% TFA) | 0.47±0.10 | 0.45±0.16 | −2.75±28.47 | N.S. | ||
| DPA n-3 (μg/ml) | 14±4.22 | 13.18±3.25 | −2.77±21.18 | N.S. | ||
| DPAn-3 (% TFA) | 0.46±0.11 | 0.44±0.09 | −3.47±15.85 | N.S. | ||
| DHA (μg/ml) | 33.73±12.18 | 33.43±11.62 | 1.53±22.2 | N.S. | ||
| DHA (% TFA) | 1.13±0.42 | 1.11±0.35 | 1.75±20.39 | N.S. | ||
| Tot LC n-3 (μg/ml) | 62.93±16.52 | 60.78±16.78 | −1.94±17.43 | N.S. | ||
| Tot LC n-3 (% TFA) | 2.08±0.50 | 2.02±0.50 | −2.12±14.3 | N.S. | ||
| AA/EPA | 17.17±4.99 | 19.37±7.59 | 15.66±36.52 | N.S. | ||
| DPA n-6/DHA | 0.24±0.08 | 0.27±0.12 | 10.24±21.01 | N.S. |
Values are Means±SD.
“% change” is the change from the baseline value to the 3-month value, expressed as the percentage of the baseline value.
Comparisons between baseline and end-of-trial FA values were done with the Wilcoxon matched-pairs signed-ranks test.